Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | QPCT | Q16769 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095827 | 0.85 | CYP11B1 (0.54) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL27992982 | 0.84 | CYP11B1 (0.50) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL2226543 | 0.84 | HDAC1 (0.52) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL12844399 | 0.84 | CYP11B1 (0.54) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL2821115 | 0.81 | HDAC1 (0.56) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL8570310 | 0.81 | HDAC1 (0.56) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL7037388 | 0.80 | HDAC1 (0.49) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL1567261 | 0.80 | HDAC1 (0.59) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL8971551 | 0.80 | HDAC1 (0.55) | CYP11B1CYP11B2HDAC1HDAC2QPCT | |
| SCHEMBL8911377 | 0.80 | HDAC1 (0.55) | CYP11B1CYP11B2HDAC1HDAC2QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | claimed |
| US-20020077302-A1 | Tricyclic erythromycin derivatives | PFIZER PRODUCTS INC. | 2002-06-20 | — | — | US | claimed |
| US-20020061856-A1 | Novel tricyclic erythromycin derivatives | PFIZER INC. | 2002-05-23 | — | — | US | claimed |
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | WU YONG-JIN (US) | 2001-08-23 | — | — | US | claimed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | claimed |
| US-6248719-B1 | Tricyclic 3-keto derivatives of 6-O-methylerthromycin | PFIZER INC | 2001-06-19 | — | — | US | claimed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020077302-A1 | Tricyclic erythromycin derivatives | PFIZER PRODUCTS INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020061857-A1 | 9-amino-3-oxo erythromycin derivatives | PFIZER INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020061856-A1 | Novel tricyclic erythromycin derivatives | PFIZER INC. | 2002-05-23 | — | — | US | disclosed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | disclosed |
| US-6248719-B1 | Tricyclic 3-keto derivatives of 6-O-methylerthromycin | PFIZER INC | 2001-06-19 | — | — | US | disclosed |
| US-6162794-A | Erythromycin derivatives | PFIZER INC. (US) | 2000-12-19 | — | — | US | disclosed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998051696-A1 | ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077302-A1 | Tricyclic erythromycin derivatives | MRPL21, CYP7A1, CYP3A7 | CYP11B1 127/4885CYP11B2 217/4885HDAC1 693/4885 |
| US-20020061856-A1 | Novel tricyclic erythromycin derivatives | MRPL21, CYP7A1, CYP3A7 | CYP11B1 97/4885CYP11B2 162/4885HDAC1 507/4885 |
| US-20020061857-A1 | 9-amino-3-oxo erythromycin derivatives | MRPL21, MRPL9, Q6ZSR9 | CYP11B1 230/4885CYP11B2 431/4885HDAC1 3060/4885 |
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | CYP7A1, HSD17B7, CYP51A1 | CYP11B1 12/4885CYP11B2 23/4885HDAC1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.